Biopharma & Life Sciences
Kura Oncology Executive Compensation (FY25)
KURA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Troy Wilson | Latest say-on-pay support = June 4, 2026 |
Free for 3 days · no card
See how Kura Oncology’s pay stands against its peers
- Kura Oncology's company dashboard and its AI-written, board-ready brief, every figure cited to the filing
- Where Kura Oncology sits against its disclosed peer group, with custom peer reruns and governance screens
- Every other company we cover, with alerts when they file
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Data as of November 22, 2026Latest filing (8-K): June 4, 2026
205 figures on this page: 198 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Troy Wilson: $6,239,098 → $4,735,016 (24.1% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Kura Oncology's chief executive and what were they paid?
Total compensation for Troy Wilson, President and Chief Executive Officer, came to $4,735,016 in fiscal 2025. Wilson's total moved 24.1% lower from the $6,239,098 reported for fiscal 2024.
What was Kura Oncology's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 97.7% of votes cast for or against in favor at the meeting held June 4, 2026.
Which companies are in Kura Oncology's peer group?
The disclosed peer group includes Arcus Biosciences, Arvinas, Cogent Biosciences, Crinetics Pharmaceuticals and Day One Biopharmaceuticals, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Troy Wilson President and Chief Executive Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Stephen Dale Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Kathleen Ford Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Kirsten Flowers Former Chief Commercial and Corporate Strategy Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Marc Grasso Former Chief Financial Officer and Chief Business Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Troy Wilson President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Kathleen Ford Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Troy Wilson President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Stephen Dale Former Chief Medical Officer Departed during or after this year | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Kathleen Ford Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Teresa Bair Chief Legal Officer and Secretary | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Troy Wilson President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Brian Powl Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Kathleen Ford Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Kathleen Ford | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Stephen Dale | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Teresa Bair | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Teresa Bair | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Troy E. Wilson | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2022, 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Kathleen Ford | Option | ◇ | — | ◇ | February 15, 2033 |
| Option | ◇ | — | ◇ | January 1, 2034 | |
| Option | ◇ | — | ◇ | January 1, 2035 | |
| Option | ◇ | — | ◇ | January 25, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | — | — | ◇ | August 8, 2029 | |
| Option | — | — | ◇ | January 29, 2030 | |
| Option | — | — | ◇ | January 25, 2031 | |
| Troy Wilson | Option | ◇ | — | ◇ | January 25, 2032 |
| Option | ◇ | — | ◇ | February 15, 2033 | |
| Option | ◇ | — | ◇ | January 1, 2034 | |
| Option | ◇ | — | ◇ | January 1, 2035 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | — | — | ◇ | January 22, 2027 | |
| Option | — | — | ◇ | January 23, 2028 | |
| Option | — | — | ◇ | January 21, 2029 | |
| Option | — | — | ◇ | January 29, 2030 | |
| Option | — | — | ◇ | January 25, 2031 | |
| Brian Powl | Option | ◇ | — | ◇ | August 13, 2033 |
| Option | ◇ | — | ◇ | January 1, 2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | January 1, 2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Faheem Hasnain | ◇ | — | ◇ | — | — | — | ◇ |
Mary T. Szela | ◇ | — | ◇ | — | — | — | ◇ |
Carol Schafer | ◇ | — | ◇ | — | — | — | ◇ |
Thomas Malley | ◇ | — | ◇ | — | — | — | ◇ |
Helen Collins, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Diane Parks | ◇ | — | ◇ | — | — | — | ◇ |
Michael Vasconcelles, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Troy E. Wilson, Ph.D., J.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Arcus Biosciences RCUS
- Arvinas ARVN
- Cogent Biosciences COGT
- Crinetics Pharmaceuticals CRNX
- Day One Biopharmaceuticals DAWN
- IDEAYA Biosciences IDYA
- Iovance Biotherapeutics IOVA
- iTeos Therapeutics ITOS
- Janux Therapeutics JANX
- Kymera Therapeutics KYMR
- Nuvalent NUVL
- Relay Therapeutics RLAY
- Revolution Medicines RVMD
- SpringWorks Therapeutics SWTX
- Structure Therapeutics GPCR
- Summit Therapeutics SMMT
- Syndax Pharmaceuticals SNDX
- Xencor XNCR
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 4, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 5, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 5, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 31, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 21, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 22, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 24, 2020 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Kura Oncology disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Kura Oncology sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation ReportWritten compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation ReportBoard and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance ReportRealizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
205 figures on this page: 198 cited to the filing that reported them, 7 calculated from figures it prints.
198 cited to the filing
7 calculated from the filing
Documents cited
- 0001193125-26-257368Proposal 3. Advisory Vote on Executive Compensation For Against Abstain Broker Non-Votes
- 0001193125-26-151335Non-Employee Director Compensation
- 0000950170-25-083046
- 0000950170-25-053335
- 0000950170-24-070584Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-24-044066Summary Compensation Table for Fiscal
- 0000950170-23-026086Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-23-012096
- 0000950170-22-012040Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-21-034591Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001564590-20-030805Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kura Oncology executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KURA (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kura Oncology and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Kura Oncology discloses
The companies named in KURA's own disclosed peer group.
Arcus BiosciencesArvinasCogent BiosciencesCrinetics PharmaceuticalsDay One BiopharmaceuticalsIDEAYA BiosciencesIovance BiotherapeuticsiTeos TherapeuticsJanux TherapeuticsKymera TherapeuticsNuvalentRelay TherapeuticsRevolution MedicinesSpringWorks TherapeuticsStructure TherapeuticsSummit TherapeuticsSyndax PharmaceuticalsXencor
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}